DUBLIN–(BUSINESS WIRE)–The “Anti-Asthmatics And COPD Drugs Global Market Opportunities And Strategies To 2030: COVID 19 Implications and Growth” report has been added to ResearchAndMarkets.com’s offering.
This report provides the strategists, marketers and senior management with the critical information they need to assess the demand for anti-asthmatics and COPD drugs market which play a critical role in the treatment of patients with Covid 19.
The global anti-asthmatics and COPD drugs market reached a value of nearly $40,162.1 million in 2019, having grown at a compound annual growth rate (CAGR) of 4.4% since 2015. The global anti-asthmatics and COPD drugs market is expected to grow from $40,162.1 million in 2019 to about $49,384.3 million in 2020 due to an increase in demand for the use of anti-asthmatics and COPD drugs in the treatment of Covid-19 patients.
The global anti-asthmatics and COPD drugs market is expected to grow at a CAGR of 4.1% to nearly $47,176.2 million by 2023. Also, the market is expected to grow to $51,164.1 million in 2025 at a CAGR of 4.1% and to $63,579.9 million in 2030 at a CAGR of 4.4%.
Reasons to Purchase
- Outperform competitors using accurate up to date demand-side dynamics information.
- Understand how the market is experiencing rapid growth due to the coronavirus and how it is likely to stabilize as the impact of the virus abates.
- Identify growth segments for investment.
- Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
- Create regional and country strategies on the basis of local data and analysis.
- Stay abreast of the latest customer and market research findings
- Benchmark performance against key competitors.
- Develop strategies based on likely future developments.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Gain a global perspective on the development of the market.
This report describes and evaluates the global anti-asthmatics and COPD drugs market. It covers two five-year periods, one three-year period, and one six-year period including, 2015 to 2019, termed the historic period, and 2019 to 2023 forecast period, 2023-2025 forecast period and 2025 -2030 the forecast period.
Growth in the historic period resulted from increased prevalence of respiratory diseases, increasing incidence of tobacco smoking, global warming, geriatric population, new methods for drug discovery, and rise in healthcare expenditure. Factors that negatively affected growth in the historic period were expiration of patents and political uncertainties.
Going forward, the increased popularity of e-cigarettes/vaping, rising obesity levels, technology, large pool of undiagnosed population, use of anti-asthmatics and COPD drugs to treat COVID-19 patients, and increasing consumption of fats are expected to drive the market. Factors that could hinder the growth of the anti-asthmatics and COPD drugs market in the future include side effects associated with respiratory drugs, reduction in free trade, and stringent regulations.
Key Topics Covered:
1. Anti-Asthmatics And COPD Drugs Market Executive Summary
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
6. Introduction
7. Anti-Asthmatics And COPD Drugs Market Characteristics
8. Anti-Asthmatics And COPD Drugs Market, Supply Chain Analysis
8.1.1. Raw Material And Equipment Procurement
8.1.2. Manufacturing, Processing and Packaging
8.1.3. Distribution
8.1.4. Physicians
8.1.5. End users
9. Anti-Asthmatics And COPD Drugs Market, Product Pipeline Analysis
10. Anti-Asthmatics And COPD Drugs Market, Top 10 Leading Drugs Sales
10.1.1. Ellipta
10.1.2. Spiriva
10.1.3. Symbicort
10.1.4. Advair
10.1.5. Pulmicort
10.1.6. Ventolin
10.1.7. Xolair
10.1.8. Nucala
10.1.9. Flovent
10.1.10. Fasenra
11. Anti-Asthmatics And COPD Drugs Market, Patent Analysis Of Leading Drugs
11.1.1. Background
11.1.2. Innovators
12. Anti-Asthmatics And COPD Drugs Market, Customer Information
12.1. Majority Of Australian COPD Patients Are Physically Inactive And Obese
12.2. Britons Experience Inadequate Treatment Of COPD
12.3. COPD Patients Are More Likely To Be Current Daily Smokers Or Ex-Smokers
12.4. Uncontrolled Asthma Patients Face Recurring Symptoms And Doctor Visits
12.5. Uncontrolled Asthma Patients Struggle With Mobility Issues
13. Impact of COVID-19 On The Anti-Asthmatics And COPD Drugs Market
13.1. Consumer Perception
13.2. High Mortality Among Asthma Patients
13.3. Anti-Asthmatic And COPD Drugs Used In COVID-19 Treatment
14. Anti-Asthmatics And COPD Drugs Market Regulatory Landscape
15. Anti-Asthmatics And COPD Drugs Market Trends And Strategies
15.1. Collaborations In The Anti-Asthmatics and COPD Drugs Market
15.2. Increasing Demand For Personalized Medicines
15.3. Demand For Aerosol Respiratory Drugs
15.4. Use Of Biomarker For Precision Medicine
15.5. Rise Of Generic Respiratory Drugs
15.6. Combination Drug Therapy To Treat COPD
15.7.New Biologic Therapy Medicines To Treat Severe Asthma
16. Asthma And COPD Prevalence Overview
16.1. Asthma
16.2. COPD
17. Global Anti-Asthmatics And COPD Drugs Market Size And Growth
17.1. Market Size
17.2. Historic Market Growth, 2015 – 2019, Value ($ Million)
17.3. Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
18. Anti-Asthmatics And COPD Drugs Market, Regional And Country Analysis
Companies Mentioned
- Abbott Laboratories
- Ache
- Adcock Ingram
- Apotex Inc.
- ASGEN Pharmaceutical Co., Ltd.
- Aspen Nigeria
- AstraZeneca plc.
- Aurobindo Pharma Limited
- Bayer
- Biolab Farmaceuticad
- Boehringer Ingelheim
- Bristol Myers Squibb
- Chiesi Farmaceutici S.p.A.
- China Meheco Group Co., Ltd
- China National Pharmaceutical Group Co., Ltd. (Sinopharm)
- Cipla Limited
- Cipla Medpro South Africa (Pty) Limited
- Cristalia
- Daewoong Pharmaceutical Co., Ltd.
- EMS Pharma
- Eurofarma
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc.
- Hanmi Pharmaceutical
- Hypermarcas
- Jiangsu Hengrui Medicine Co., Ltd.
- Julphar
- KYORIN Holdings, Inc.
- Libbs
- Lupin Limited
- Merck & Co., Inc.
- Mylan
- Neopharma
- Nichi-Iko Pharmaceutical Co., Ltd.
- Novartis
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer
- Sanofi S.A.
- Shanghai Acebright Pharmaceuticals Group Co., Ltd.
- Shanghai Anovent Pharma
- Sumitomo Dainippon Pharma Co., Ltd.
- Teva Pharmaceutical Industries Limited
- Vectura Group
For more information about this report visit https://www.researchandmarkets.com/r/pyma3k
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900